Management of Vyvanse-Related Appetite Suppression and Weight Loss
For appetite loss and significant weight loss on Vyvanse 20mg, give the medication with meals and provide a high-calorie drink or snack late in the evening when the stimulant effects have worn off 1.
Understanding the Problem
Decreased appetite and weight loss are expected and common adverse effects of Vyvanse (lisdexamfetamine). The FDA label documents that 27-34% of patients experience decreased appetite, making it one of the most frequent side effects 2. At the 20mg dose you're using, this is on the lower end of the dosing spectrum (therapeutic range 30-70mg), yet appetite suppression can still be significant.
Immediate Management Strategy
Timing and Nutritional Interventions
The guideline-recommended approach involves strategic timing 1:
- Administer Vyvanse WITH meals (not before) to ensure food intake occurs while appetite is still present
- Provide high-calorie drinks or snacks in the late evening (after 6-8 PM) when medication effects have diminished and appetite returns
- Focus on calorie-dense foods during the evening window to compensate for daytime intake reduction
Monitoring Requirements
Weight monitoring is critical, particularly in pediatric patients. The FDA label shows dose-dependent weight loss even at lower doses 2:
- At 30mg (just above your dose): mean weight loss of 0.9-2.7 lbs over 4 weeks
- Long-term data shows consistently medicated pediatric patients experience slowing in growth rate with age/sex-normalized percentile changes of -13.4 over one year 2
When to Adjust or Change Medication
Dose Reduction
If nutritional interventions fail and weight loss continues to be "significant" (generally defined as >5% body weight or crossing percentile lines), reduce the dose before considering medication discontinuation 1. Even a reduction from 20mg to 10mg may preserve therapeutic benefit while reducing appetite suppression.
Medication Switching
If dose reduction compromises ADHD symptom control, consider switching to:
- Non-stimulant alternatives (atomoxetine, guanfacine, or clonidine) which have different side effect profiles 3
- Atomoxetine also causes decreased appetite but may be better tolerated in some patients
- Alpha-2 agonists (guanfacine/clonidine) do not typically cause appetite suppression
Important Clinical Context
Growth Considerations in Pediatric Patients
The 2019 AAP guidelines emphasize that stimulant-related growth delays show 3:
- Temporary slowing (average 2cm less height, 2.7kg less weight over 3 years)
- No evidence of growth rebound during continued treatment
- This makes ongoing monitoring essential, not optional
Drug Holidays
While not explicitly mentioned in the guidelines for appetite management, some clinicians use weekend or summer "drug holidays" to allow catch-up growth and weight gain. However, this must be balanced against symptom control needs.
What NOT to Do
Do not simply accept significant weight loss as inevitable. The evidence shows this is a manageable side effect with proper intervention 1. The fact that you're at 20mg (a relatively low dose) means you have room to reduce further if needed while potentially maintaining some therapeutic benefit.
Do not wait for "significant" weight loss to become severe. Early intervention with nutritional strategies is more effective than trying to reverse substantial weight loss later.
Clinical Pitfalls
- Mistaking behavioral food refusal for medication effect: Ensure the decreased appetite is truly medication-related and not oppositional behavior or other causes
- Inadequate calorie compensation: Evening snacks must be genuinely high-calorie (not just "healthy" options) to compensate for daytime deficits
- Insufficient monitoring frequency: Weight should be checked at least monthly during dose titration and when side effects are present